Literature DB >> 15220463

Epstein-Barr virus latent membrane protein LMP-2A is sufficient for transactivation of the human endogenous retrovirus HERV-K18 superantigen.

Natalie Sutkowski1, Gang Chen, German Calderon, Brigitte T Huber.   

Abstract

Superantigens are microbial proteins that strongly stimulate T cells. We described previously that the Epstein-Barr virus (EBV) transactivates a superantigen encoded by the human endogenous retrovirus, HERV-K18. We now report that the transactivation is dependent upon the EBV latent cycle proteins. Moreover, LMP-2A is sufficient for induction of HERV-K18 superantigen activity.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15220463      PMCID： PMC434102          DOI： 10.1128/JVI.78.14.7852-7860.2004

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  64 in total

1.  Linkage between STAT regulation and Epstein-Barr virus gene expression in tumors.

Authors:  H Chen; J M Lee; Y Zong; M Borowitz; M H Ng; R F Ambinder; S D Hayward
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

2.  Interferon-alpha inhibits Stat5 DNA-binding in IL-2 stimulated primary T-lymphocytes.

Authors:  Sven Erickson; Sampsa Matikainen; Lena Thyrell; Olle Sangfelt; Ilkka Julkunen; Stefan Einhorn; Dan Grandér
Journal:  Eur J Biochem       Date:  2002-01

3.  Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to LMP2A antigen: a potential treatment strategy for Epstein-Barr virus--positive Hodgkin's lymphoma.

Authors:  B Gahn; F Siller-Lopez; A D Pirooz; E Yvon; S Gottschalk; R Longnecker; M K Brenner; H E Heslop; E Aguilar-Cordova; C M Rooney
Journal:  Int J Cancer       Date:  2001-09-01       Impact factor: 7.396

4.  Recombinant adenovirus coexpressing covalent peptide/MHC class II complex and B7-1: in vitro and in vivo activation of myelin basic protein-specific T cells.

Authors:  J Chen; B T Huber; R J Grand; W Li
Journal:  J Immunol       Date:  2001-08-01       Impact factor: 5.422

Review 5.  LMP1 structure and signal transduction.

Authors:  A G Eliopoulos; L S Young
Journal:  Semin Cancer Biol       Date:  2001-12       Impact factor: 15.707

6.  Transgenic expression of the coxsackie/adenovirus receptor enables adenoviral-mediated gene delivery in naive T cells.

Authors:  Y Y Wan; R P Leon; R Marks; C M Cham; J Schaack; T F Gajewski; J DeGregori
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

7.  Epstein-Barr virus LMP2A-induced B-cell survival in two unique classes of EmuLMP2A transgenic mice.

Authors:  R G Caldwell; R C Brown; R Longnecker
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

8.  Epstein-Barr virus recombinants from overlapping cosmid fragments.

Authors:  B Tomkinson; E Robertson; R Yalamanchili; R Longnecker; E Kieff
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

9.  The LMP2A ITAM is essential for providing B cells with development and survival signals in vivo.

Authors:  M Merchant; R G Caldwell; R Longnecker
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

10.  Epstein-Barr virus latent membrane protein 2A (LMP2A) employs the SLP-65 signaling module.

Authors:  N Engels; M Merchant; R Pappu; A C Chan; R Longnecker; J Wienands
Journal:  J Exp Med       Date:  2001-08-06       Impact factor: 14.307
View more
  33 in total

1.  Absence of interaction between porcine endogenous retrovirus and porcine cytomegalovirus in pig-to-baboon renal xenotransplantation in vivo.

Authors:  Jay A Fishman; David H Sachs; Kazuhiko Yamada; Robert A Wilkinson
Journal:  Xenotransplantation       Date:  2018-04-06       Impact factor: 3.907

2.  Epstein-Barr-virus-encoded LMP2A induces primary epithelial cell migration and invasion: possible role in nasopharyngeal carcinoma metastasis.

Authors:  Dirk M Pegtel; Aravind Subramanian; Tzung-Shiahn Sheen; Ching-Hwa Tsai; Todd R Golub; David A Thorley-Lawson
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

Review 3.  The virome in mammalian physiology and disease.

Authors:  Herbert W Virgin
Journal:  Cell       Date:  2014-03-27       Impact factor: 41.582

4.  Expression and activation by Epstein Barr virus of human endogenous retroviruses-W in blood cells and astrocytes: inference for multiple sclerosis.

Authors:  Giuseppe Mameli; Luciana Poddighe; Alessandra Mei; Elena Uleri; Stefano Sotgiu; Caterina Serra; Roberto Manetti; Antonina Dolei
Journal:  PLoS One       Date:  2012-09-27       Impact factor: 3.240

5.  Chimerically fused antigen rich of overlapped epitopes from latent membrane protein 2 (LMP2) of Epstein-Barr virus as a potential vaccine and diagnostic agent.

Authors:  Xiaoyun Lin; Shao Chen; Xiangyang Xue; Lijun Lu; Shanli Zhu; Wenshu Li; Xiangmin Chen; Xiaozhi Zhong; Pengfei Jiang; Torsoo Sophia Sename; Yi Zheng; Lifang Zhang
Journal:  Cell Mol Immunol       Date:  2015-04-13       Impact factor: 11.530

Review 6.  The retrovirus/superantigen hypothesis of multiple sclerosis.

Authors:  Alexander Emmer; Martin S Staege; Malte E Kornhuber
Journal:  Cell Mol Neurobiol       Date:  2014-08-20       Impact factor: 5.046

Review 7.  Endogenous retrovirus-K and nervous system diseases.

Authors:  Mamneet Manghera; Jennifer Ferguson; Renée Douville
Journal:  Curr Neurol Neurosci Rep       Date:  2014-10       Impact factor: 5.081

8.  The potential role of human endogenous retrovirus K10 in the pathogenesis of rheumatoid arthritis: a preliminary study.

Authors:  H D Ejtehadi; G L Freimanis; H A Ali; S Bowman; A Alavi; J Axford; R Callaghan; P N Nelson
Journal:  Ann Rheum Dis       Date:  2005-09-28       Impact factor: 19.103

Review 9.  Gene sharing between Epstein-Barr virus and human immune response genes.

Authors:  David H Dreyfus
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

10.  B cells and monocytes from patients with active multiple sclerosis exhibit increased surface expression of both HERV-H Env and HERV-W Env, accompanied by increased seroreactivity.

Authors:  Tomasz Brudek; Tove Christensen; Lars Aagaard; Thor Petersen; Hans J Hansen; Anné Møller-Larsen
Journal:  Retrovirology       Date:  2009-11-16       Impact factor: 4.602
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.